{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:31:00Z","timestamp":1761561060746,"version":"3.32.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00296-006-0144-1","type":"journal-article","created":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T13:38:54Z","timestamp":1149082734000},"page":"1158-1160","source":"Crossref","is-referenced-by-count":7,"title":["Psoriasis onset during infliximab treatment: description of two cases"],"prefix":"10.1007","volume":"26","author":[{"given":"Alessandro","family":"Volpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Caramaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pieropan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Maria","family":"Bambara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Biasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,1]]},"reference":[{"key":"144_CR1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu R, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"144_CR2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534\u2013542","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"144_CR3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64(Suppl 2):18\u201323","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"144_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/ard.2004.032276","volume":"64","author":"LS Winterfield","year":"2005","unstructured":"Winterfield LS, Menter A, Gordon K, Gottlieb A (2005) Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64(suppl 2):87\u201390","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 74","key":"144_CR5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/rheumatology\/keh617","volume":"32","author":"EC Keystone","year":"2005","unstructured":"Keystone EC (2005) Safety of biologic therapies\u2014an update. J Rheumatol 32(Suppl 74):8\u201312","journal-title":"J Rheumatol"},{"key":"144_CR6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/archderm.138.9.1258","volume":"138","author":"G Vegara","year":"2002","unstructured":"Vegara G, Silvestre JF, Betloch I, Albares MP, Pascual JC (2002) Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138:1258\u20131259","journal-title":"Arch Dermatol"},{"key":"144_CR7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(02)09800-8","volume":"360","author":"AK Mohan","year":"2002","unstructured":"Mohan AK, Edwards ET, Cot\u00e9 TR, Siegel JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646","journal-title":"Lancet"},{"key":"144_CR8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","volume":"1","author":"N Tsankov","year":"2000","unstructured":"Tsankov N, Angelova I, Kazandjieva J (2000) Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 1:159\u2013165","journal-title":"Am J Clin Dermatol"},{"key":"144_CR9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.20954","volume":"52","author":"B Grinblat","year":"2005","unstructured":"Grinblat B, Scheinberg M (2005) Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 52:1333\u20131334","journal-title":"Arthritis Rheum"},{"key":"144_CR10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","volume":"151","author":"O Dereure","year":"2004","unstructured":"Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ (2004) Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol 151:506\u2013507","journal-title":"Br J Dermatol"},{"issue":"Suppl","key":"144_CR11","first-page":"277","volume":"63","author":"S Kary","year":"2004","unstructured":"Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee HH, Staender E, Maa\u03b2 U, Neeck G, Renelt M, Sterry W, Burmester G (2004) New onset or aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNF\u03b1 antagonists: report of 8 cases (abstract). Ann Rheum Dis 63(Suppl):277","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"144_CR12","first-page":"405","volume":"63","author":"H Haibel","year":"2004","unstructured":"Haibel H, Spiller I, Strasser C (2004) Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNF\u03b1 blocking agents (abstract). Ann Rheum Dis 63(Suppl):405","journal-title":"Ann Rheum Dis"},{"key":"144_CR13","first-page":"439","volume":"3","author":"M Thurber","year":"2004","unstructured":"Thurber M, Feasel A, Stroehlein J, Hymes SR (2004) Pustolar psoriasis induced by infliximab. Drugs Dermatol 3:439\u2013440","journal-title":"Drugs Dermatol"},{"key":"144_CR14","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy. A paradoxical adverse reaction. Arthritis Rheum 52:2513\u20132518","journal-title":"Arthritis Rheum"},{"key":"144_CR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","volume":"38","author":"MM Verea","year":"2004","unstructured":"Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E (2004) Psoriasiform eruption induced by infliximab. Ann Pharmacother 38:54\u201357","journal-title":"Ann Pharmacother"},{"key":"144_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DL (1981) A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"144_CR17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","volume":"89","author":"EW Lindstedt","year":"2005","unstructured":"Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533\u2013536","journal-title":"Br J Ophthalmol"},{"key":"144_CR18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bjo.87.7.925","volume":"87","author":"AR Reddy","year":"2003","unstructured":"Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925","journal-title":"Br J Ophthalmol"},{"key":"144_CR19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"N Shakoor","year":"2002","unstructured":"Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579\u2013580","journal-title":"Lancet"},{"key":"144_CR20","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","volume":"50","author":"M Aringer","year":"2004","unstructured":"Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50:3161\u20133169","journal-title":"Arthritis Rheum"},{"key":"144_CR21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","volume":"94","author":"AP Cope","year":"1994","unstructured":"Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749\u2013760","journal-title":"J Clin Invest"},{"key":"144_CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","volume":"60","author":"L Berg","year":"2001","unstructured":"Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60:133\u2013139","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-006-0144-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0144-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:19:59Z","timestamp":1736396399000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-006-0144-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s00296-006-0144-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}